Donnerstag, 17.02.19 05:07
Bildquelle: iStock by Getty Images


Quelle: boerse.de

News und Analysen

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)

KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced presentation of the full results from the pivotal Phase ...weiterlesen

Seite: 1 | 2 | 3 | 4 | 5 | 6 | ... | 10478